CN116063205B - Lipid compound containing alkylated carbamate bond and application thereof - Google Patents

Lipid compound containing alkylated carbamate bond and application thereof Download PDF

Info

Publication number
CN116063205B
CN116063205B CN202310007835.9A CN202310007835A CN116063205B CN 116063205 B CN116063205 B CN 116063205B CN 202310007835 A CN202310007835 A CN 202310007835A CN 116063205 B CN116063205 B CN 116063205B
Authority
CN
China
Prior art keywords
lipid
compound
acid
composition
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310007835.9A
Other languages
Chinese (zh)
Other versions
CN116063205A (en
Inventor
李忠宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weishikang Animal Health (Shanghai) Co.,Ltd.
Original Assignee
Shanghai Zhenyao Biotechnology Partnership LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zhenyao Biotechnology Partnership LP filed Critical Shanghai Zhenyao Biotechnology Partnership LP
Priority to CN202310007835.9A priority Critical patent/CN116063205B/en
Publication of CN116063205A publication Critical patent/CN116063205A/en
Application granted granted Critical
Publication of CN116063205B publication Critical patent/CN116063205B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a polyurethane containing alkylation urethane bondThe lipid compound and the application thereof belong to the field of biological medicine, and the lipid compound is a compound with the following structure:

Description

Lipid compound containing alkylated carbamate bond and application thereof
Technical Field
The invention relates to the field of biological medicine, in particular to a pharmaceutical composition containing an alkylated carbamate bondIs provided.
Background
Gene therapy (gene therapy) is a therapeutic method for correcting or compensating diseases caused by defective or abnormal genes by introducing exogenous genes into target cells. Nucleic acid vaccine (nucleic acid vaccine), also known as genetic vaccine (genomic vaccinee), refers to a vaccine that is prepared by introducing a nucleic acid sequence (such as DNA, mRNA, etc.) encoding an immunogenic protein or polypeptide into a host, expressing the immunogenic protein or polypeptide by the host cell, and inducing the host cell to produce an immune response against the immunogen, thereby achieving the purpose of preventing and treating diseases. Among them, ensuring the smooth introduction of foreign genes is an extremely important part of gene therapy and immunization with genetic vaccines. Among the methods of gene delivery, methods of developing suitable lipid nanoparticles (i.e., LNP, lipid Nanoparticle) to encapsulate nucleic acids, target them to target cells, and deliver nucleic acids of specific genes into cells are increasingly being used by scientists.
One obvious difference between nucleic acid drugs and common chemical drugs is that nucleic acids carry a large number of phosphates, thus being negatively charged and of large molecular weight. In order to enable better encapsulation by lipid nanoparticles, various lipid compounds such as ionizable lipids have been developed.
The invention relates to an alkyl-containing urethane bondMay have charge-altering properties with environmental pH. That is, positively charged at acidic pH and neutral at physiological pH. Parameters such as physicochemical properties, concentration and the like influence the surface charge of the LNP under different pH conditions. This state of charge can affect its immune recognition in the blood, blood clearance and tissue distribution, and its ability to escape endosomes within the cell, which is critical for intracellular delivery of nucleic acids.
"Lipid Nanoparticle (LNP)" refers to a nanostructure formed by encapsulating or associating a drug such as a nucleic acid to be delivered with a lipid compound (e.g., an ionizable lipid compound) or the like, and has a bilayer or multilayer film structure. The nanometer particle is distributed with ionizable lipid compound, other lipid auxiliary materials and nucleic acid wrapped in the nanometer particle. LNP and compositions thereof can be used for a variety of purposes, including delivering encapsulated or associated (e.g., complexed) therapeutic agents such as nucleic acids to cells in vitro and in vivo, thereby inducing expression of a protein of interest or inhibiting expression of a target gene.
The development of LNP overcomes a number of difficulties faced by nucleic acid drugs in clinical applications, such as: first, nucleic acid molecules are susceptible to degradation by nucleases found in organisms or in nature; second, nucleic acid molecules have limited ability to enter cells, interact with target organelles, modulate target gene expression or target protein expression; third, intracellular delivery is inefficient (e.g., cannot escape from endosomes).
Nucleic acid deliveryThe core of delivery mainly includes a carrier and mRNA, wherein the core of the carrier is an ionizable lipid, an ionizable lipid molecule capable of overcoming the above problems is critical for nucleic acid delivery, and although commercially available ionizable lipid compounds have been successful, there are various problems such as a large side effect due to low delivery efficiency and increased use amount of the lipid compound. In order to increase the delivery efficiency of nucleic acids and to increase the safety of LNPs, the present invention provides a nucleic acid delivery system comprising an alkylated urethane linkageSolves such problems.
Disclosure of Invention
To solve the defects in the prior art, the invention aims to provide a catalyst containing an alkylated carbamate bond The mRNA-LNP nucleic acid transfection efficiency prepared by the ionizable lipid compound with a brand new structure is high, the biocompatibility is good, and the stability is high.
In order to achieve the above object, the present invention adopts the following technical scheme:
a lipid compound, characterized in that said compound has the structure:
wherein n is 1 And n 2 Each independently is 0, 1,2, 3, 4, 5, 6, 7, 8, 9, or 10;
G 1 、G 2 each independently is a C1-C10 alkylene group;
R 1 、R 2 、R 3 、R 4 each independently is a H, C1-C20 linear or branched alkyl group, or a C2-C20 linear or branched alkenyl group;
G 3 an alkylene group of 1 to 10 carbon atoms; or G 3 For (CH 2) a -O-(CH2) b Wherein a, b are each independently 1,2, 3, 4, 5, 6, 7, 8 or 9, and a+b is an integer from 2 to 10;
L 1 is- (C=O) O-, -O (C=O) -, -NH (C=O) O-, -O (C=O) NH-; -O (c=o) O-, - (c=o) S-, -S (c=o) -,
wherein R5 or R6 is a C1-C5 straight or branched chain alkanyl radical;
L 2 is thatWherein R is 5 Or R is 6 Is a C1-C5 straight or branched chain alkane group.
The lipid compound of the invention takes a tertiary amine-containing group as a head part, two hydrophobic groups as tail parts, and at least one hydrophobic tail part of the two hydrophobic groups is introduced with an alkylated urethane bond while being respectively introduced with- (C=O) O-, -O (C=O) -, -NH (C=O) O-, -O (C=O) NH-, -O (C=O) O-, - (C=O) S-, -S (C=O) -, and the alkylated urethane bond. The structure can enable the two hydrophobic tails to present a three-dimensional conical structure in the buffer solution, and the structure can promote the membrane fusion capability of LNP, improve the escape capability of endosome and improve the transfection efficiency; any modification of the lipid molecules based on such structures is within the scope of the present invention and is suggested by the present invention.
One of the lipid compounds described above, as an example, -CH (R 1 )R 2 and-CH (R) 3 )R 4 Each independently selected from the group consisting of:
any one of the following; the structure of the hydrophobic group is not limited, so long as the three-level amine-containing group is adopted as the head, two hydrophobic groups are adopted as the tail, the two hydrophobic groups are respectively introduced into the two hydrophobic groups as- (C=O) O-, -O (C=O) -, -NH (C=O) O-; -O (c=o) NH-, -O (c=o) O-, - (c=o) S-, -S (c=o) -, alkylated urethane linkage, compounds having an alkylated urethane linkage introduced to at least one of the two hydrophobic tails, while introducing an alkylated urethane linkage, are within the scope of the present invention.
One of the lipid compounds described above, as an example, -CH (R 1 )R 2 and-CH (R) 3 )R 4 Each independently selected from the group consisting of:
any one of the following; the structure of the hydrophobic group is not limited, so long as the three-level amine-containing group is adopted as the head, two hydrophobic groups are adopted as the tail, the two hydrophobic groups are respectively introduced into the two hydrophobic groups as- (C=O) O-, -O (C=O) -, -NH (C=O) O-; -O (c=o) NH-, -O (c=o) O-, - (c=o) S-, -S (c=o) -, alkylated urethane linkage, compounds having an alkylated urethane linkage introduced to at least one of the two hydrophobic tails, while introducing an alkylated urethane linkage, are within the scope of the present invention.
One of the lipid compounds described above, as an example, -CH (R 1 )R 2 and-CH (R) 3 )R 4 Each independently selected from the group consisting of:any one of the following; it is to be noted that the junction of the hydrophobic groupThe structure is not limited as long as the tertiary amine-containing group is adopted as the head, two hydrophobic groups are adopted as the tail, and compounds which are respectively introduced into- (C=O) O-, -O (C=O) -, -NH (C=O) O-, -O (C=O) NH-, -O (C=O) O-, - (C=O) S-, -S (C=O) -, and an alkylated urethane bond and are introduced into the alkylated urethane bond are respectively introduced into the two hydrophobic tails, and at least one of the two hydrophobic tails is introduced into the alkylated urethane bond are within the protection scope of the invention.
In a most preferred embodiment, one of the lipid compounds described above is selected from the group consisting of:
a composition comprising one of the aforementioned lipid compounds, stereoisomers thereof, tautomers thereof or pharmaceutically acceptable salts thereof.
The composition is characterized in that the composition comprises: a carrier, a drug carried, a pharmaceutical adjuvant, or a combination thereof.
The composition as described above, characterized in that the carrier comprises: one or more lipid compounds, co-lipids, structural lipids, polymer conjugated lipids or a combination of several of amphiphilic block copolymers; it should be noted that: the components of the carrier composition are not limited, and may be any of those having a known composition of matter or those having an unknown composition of matter, and any of those having a lipid compound having a structure according to the present invention is within the scope of the present invention and is taught by the present invention.
The composition is characterized in that, as an example, the molar ratio of the lipid compound to the lipid aid is 0.5:1-15:1.
The composition is characterized in that, as an example, the molar ratio of the lipid compound to the structural lipid is 0.5:1 to 5:1.
The composition of the foregoing, wherein, as an example, the molar ratio of the lipid compound to the polymer conjugated lipid is from 5:1 to 250:1.
The composition is characterized in that, as an example, the molar ratio of the lipid compound to the amphiphilic block copolymer is 1:1 to 200:1.
The composition is characterized in that the carrier is lipid nanoparticles, the average size of the lipid nanoparticles is 30-200nm, and the polydispersity index of the lipid nanoparticles is less than or equal to 0.3.
The composition, characterized in that the drug carried comprises: a nucleic acid molecule, a small molecule compound, a polypeptide, or a protein, or a combination thereof; the choice and combination formulation of the drug to be carried is not limited, and any lipid compound adopting the structure of the present invention is within the scope of the present invention and is suggested by the present invention.
The composition as described above, characterized in that the pharmaceutical adjuvant comprises: a diluent, stabilizer, preservative, or lyoprotectant, or a combination thereof; the choice and combination formulation of the pharmaceutical adjuvants are not limited, and any lipid compound employing the structure of the present invention is within the scope of the present invention and is suggested by the present invention.
The invention has the advantages that:
the lipid compound of the invention takes a tertiary amine-containing group as a head part, two hydrophobic groups as tail parts, and introduces an alkylated urethane bond into the two hydrophobic groups respectively at one side of the two hydrophobic groups, wherein the two hydrophobic groups are- (C=O) O-, -O (C=O) -, -NH (C=O) O-, -O (C=O) NH-, -O (C=O) O-, - (C=O) S-, -S (C=O) -, and the alkylated urethane bond, and at the other side of the two hydrophobic tail parts are introduced with the alkylated urethane bond, so that the two hydrophobic tail parts can present a three-dimensional cone structure in a buffer solution, and LNP formed by the structural compound can promote the membrane fusion capability of the LNP, improve the escape capability of endosomes and the transfection efficiency, thereby generating stronger protein expression capability.
The lipid compounds of the present invention incorporate alkylated urethane linkages, which have good biocompatibility.
The lipid transfection efficiency of the structure of the invention is high, the safety is good, the biocompatibility is high, the synthesis steps are simple, and the lipid transfection method is suitable for biological medicine industrialization.
Drawings
FIG. 1 is a hydrogen spectrum of an F-01 lipid compound of the present invention;
FIG. 2 is a graph showing the particle size distribution of the F-01 lipid compound of the present invention;
term, english abbreviation interpretation:
nucleic acid is a generic term for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which is a biological macromolecule composed of multiple nucleotide monomers; the nucleic acid is composed of nucleotides, and the nucleotide monomers are composed of five carbon sugars, phosphate groups, nitrogen-containing bases, or any modification groups. If the five carbon sugar is ribose, then the polymer formed is RNA; if the pentose is deoxyribose, the polymer formed is DNA.
Nucleic acid molecules include single-stranded DNA, double-stranded DNA, short isoforms, mRNA, tRNA, rRNA, long non-coding RNAs (lncRNA), micronon-coding RNAs (miRNA and siRNA), telomerase RNA (Telomerase RNA Component), small molecule RNAs (snRNA and scRNA), circular RNAs (circRNA), synthetic mirnas (miRNA micrometers, miRNA agomir, miRNA antagomir), antisense DNA, antisense RNA, ribozymes (ribozyme), asymmetric interfering RNAs (aiRNA), dicer-substrate RNAs (dsRNA), small hairpin RNAs (shRNA), transfer RNAs (tRNA), messenger RNAs (mRNA), gRNA, sgRNA, crRNA or tracrRNA, locked Nucleic Acids (LNA), peptide Nucleic Acids (PNA), morpholino antisense oligonucleotides, morpholino oligonucleotides, or biospecific oligonucleotides, and the like. The examples herein are not exhaustive and can be applied to the present invention as long as they are polymerized from nucleotide monomers.
In the claims of the present invention, when "C1-C20 straight chain or branched chain alkyl" is described, it means that the group may be an alkyl group having 1 to 20 carbon atoms (e.g., 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms), and that the alkyl group is a saturated alkyl group, which may be straight chain, or have a branched structure, and that the alkyl group satisfying the number of the aforementioned carbon atoms is within the scope of the description of the term.
When describing "a C2-C20 straight or branched chain olefinic group", it is meant that the group may be an olefinic group having 2 to 20 carbon atoms (e.g., 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms), and that the alkyl group be a saturated alkyl group, which may be straight or branched, and that the olefinic group having a branched structure, satisfying the number of carbon atoms as described above, is within the scope of the description of the term. In various embodiments of the invention, the olefinic group may be a mono-olefin or a multi-olefin (e.g., a di-olefin).
When describing "C1-C5 straight or branched chain alkanyl" it is meant that the radical may be an alkanyl radical having 1-5 carbon atoms (e.g., 1,2, 3, 4, or 5 carbon atoms), which may be straight chain, or have a branched structure, and that alkanyl radicals satisfying the foregoing numbers of carbon atoms are within the scope of the term description. In various embodiments of the invention.
When "C1-C10 alkylene" is described, it is intended that the group may be an alkylene group having 1 to 10 carbon atoms (e.g., 1,2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms), which may be straight or branched.
When describing "alkylated urethane linkage" it refers toWherein R5 or R6 is a C1-C5 straight or branched chain alkanyl radical.
When "lipid compound containing urethane bond" is described, it means that the hydrophobic group of the lipid compound containsOr->Wherein R5 or R6 is a C1-C5 straight or branched chain alkanyl radical.
Pharmaceutically usable salts refer to acid addition salts or base addition salts.
Acids in which the acid addition salts include, but are not limited to: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acid-type phosphates, acetic acid, 2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, carbonic acid, cinnamic acid, citric acid, cyclic amic acid, dodecylsulfuric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxoglutaronic acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1, 5-dicarboxylic acid, naphthalene-2-sulfonic acid, 1-hydroxy-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, propionic acid, glutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, succinic acid, sulfanilic acid, tartaric acid, succinic acid, tricarboxylic acid, and quaternary ammonium acids.
Wherein the base addition salts include, for example, but are not limited to: sodium, potassium, lithium, ammonium, calcium, magnesium, ferric, cupric, manganic, and aluminum salts; organic bases include, but are not limited to, ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, dealcoholization, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procaine, hydrazinaniline, choline, betaine, bennetamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, purine, piperazine, piperidine, N-ethylpiperidine, and polyamine resins; preferably, the organic base is isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
The lipid-aiding agent comprises: phosphatidylcholine, phosphatidylethanolamine, sphingomyelin (SM), sterols and derivatives thereof, ceramide, charged lipids, or a combination of several of them; phosphatidylcholine as one preferred includes: DSPC, DPPC, DMPC, DOPC, POPC; phosphatidylethanolamine as a preferred type is DOPE; sterols as a preferred cholesterol; charged lipids are as an example DOTAP, DOTMA, 18PA; it is not intended to be exhaustive and it is within the scope of the invention to suggest any composition of lipid compounds employing the structures of the present invention. The choice of the auxiliary lipid is not limited and is not limited, and any lipid compound adopting the structure of the invention is within the scope of the invention and is taught by the invention.
Charged lipids refer to a class of lipid compounds that exist in positively or negatively charged form; the charge is independent of the pH in the physiological range, for example pH 3-9, and is not affected by pH. Charged lipids may be of synthetic or natural origin. Examples of charged lipids include, but are not limited to DOTAP, DOTMA, 18PA.
mRNA, messenger RNA, chinese translation: messenger ribonucleic acid is a single-stranded ribonucleic acid transcribed from one strand of DNA as a template and carrying genetic information to direct protein synthesis. The mRNA may be monocistronic mRNA or polycistronic mRNA. The mRNA may also contain one or more functional nucleotide analogs, examples of which include: pseudouridine, 1-methyl-pseudouridine, 5-methylcytosine, and the like. The examples herein are also not exhaustive and any modified mRNA or derivative thereof may be used in the present invention.
The small molecule compound may be an active ingredient in an agent for treatment or prophylaxis, for example: antitumor agents, antiinfectives, local anesthetics, antidepressants, anticonvulsants, antibiotics/antibacterials, antifungals, antiparasitics, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, anti-glaucoma agents, anesthetics, or imaging agents, etc., are not meant to be exhaustive.
Polypeptides are compounds formed by joining alpha-amino acids together in peptide bonds, and are proteolytic intermediates.
The protein is a substance with a certain space structure formed by the twisting and folding of a polypeptide chain consisting of amino acids in a dehydration condensation mode; the protein may be an interferon, protein hormone, cytokine, chemokine or enzyme, etc.
Diluents are any pharmaceutically acceptable water-soluble excipients known to those skilled in the art, including: amino acids, monosaccharides, disaccharides, trisaccharides, tetrasaccharides, pentasaccharides, other oligosaccharides, mannitol, dextran, sodium chloride, sorbitol, polyethylene glycol, phosphates, or derivatives thereof, and the like.
The stabilizer can be any pharmaceutically acceptable auxiliary material known to those skilled in the art: tween-80, sodium dodecyl sulfate, sodium oleate, mannitol, mannose or sodium alginate, etc.
The preservative may be any pharmaceutically acceptable preservative known to those skilled in the art, such as: thiomerosal, and the like.
The lyoprotectant may be any pharmaceutically acceptable lyoprotectant known to those skilled in the art, such as: glucose, mannitol, sucrose, lactose, trehalose, maltose, and the like.
DSPC: english name: distearoyl Phosphatidylcholine,1, 2-distearoyl-sn-glycero-3-phosphaline; chinese name: distearyl lecithin, CAS number 816-94-4.
DPPC: chinese name: dipalmitin phosphatidylcholine; english name: no. 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, CAS, 63-89-8.
DMPC: chinese name: dimyristoyl phosphatidylcholine; english name: 1, 2-Dimyristonyl-sn-glycero-3-phosphonine, CAS number 18194-24-6.
DOPC: chinese name: 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine; english name: 1, 2-diolyl-sn-glycero-3-phosphaline, CAS number 4235-95-4.
POPC: chinese name: 2-oleoyl-1-palmitoyl-glycerol-3-phosphorylcholine; english name: 2-Oleoyl-1-palmitoyl-sn-glycero-3-phosphacholine, CAS number 26853-31-6.
DOPE: chinese name: 1, 2-dioleoyl-SN-glycero-3-phosphorylethanolamine; english name: 1, 2-Dioleyl-SN-Glycero-3-PHOSPHOETHANOLAMINE, CAS: 4004-05-1.
DOTAP: chinese name: (1, 2-dioleoxypropyl) trimethylammonium chloride; english name: 1, 2-diolyl-3-trimethyllamonium-propane (chloride salt), CAS number: 132172-61-3; the chemical structural formula is shown as follows:
DOTMA: chinese name: n, N, N-trimethyl-2, 3-bis (octadeca-9-en-1-yloxy) propan-1-ammonium chloride, CAS number 1325214-86-5, chemical structural formula shown below:
18PA: CAS number: 108392-02-5, the chemical structural formula is shown as follows:
SM: chinese name: sphingomyelin (SM); english name: sphingomyelin.
PEG: chinese name: polyethylene glycol; english name: polyethylene glycol.
Amphiphilic block copolymers refer to: a block copolymer of PEG with one or more of the following polymer components, the polymer components comprising: one or more of polylactic acid-polyglycolic acid copolymer (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyorthoester, polyanhydride, poly (β -amino ester) (PBAE).
Detailed Description
The invention is described in detail below with reference to the drawings and the specific embodiments.
Lipid compounds containing urethane bonds were prepared by the preparation method of example 1 below.
Example 1:
synthesis of Compound A-I01. A-S01 (4.84 g,20.0 mmol) was dissolved in DCM (20 mL) and Et was added 3 N (3.9 mL), CDI (3.24 g,20 mmol) was reacted at 50℃for 1.5h. A-S02 (3.52 g,30.0 mmol) was then added and reacted at 50℃for 2h. Cooled to room temperature, washed successively with 5% citric acid (20 mL. Times.2), saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate and concentrated to give a crude product. The crude product was purified by column chromatography (DCM: etoh=100:1) to give 6.88g of product in yield: 89.1%.
Synthesis of Compound A-I02. A-I01 (6.88 g,17.84 mmol) was dissolved in DCM (54 mL) and PPh was added 3 (7.02 g,26.76 mmol) and CBr was added portionwise with ice bath 4 (8.87 g,26.76mmol,1.5 eq) in an ice bath for 25min. Adding 10mL of methanol to quench the reaction, and directly concentrating to obtain a crude product. The crude product was purified by column chromatography (PE: ea=10:1) to give 7.52g of product, yield: 94.0%.
Synthesis of Compound A-I03. A-I02 (1.12 g,2.5 mmol) was added to a THF (100 mL) suspension containing NaH (200 mg,5 mmol) and MeI (311 uL,5 mmol) at 0deg.C. The mixture was warmed to room temperature and stirred for 48 hours. Concentrated, sodium bicarbonate solution was added and extracted three times with ethyl acetate/petroleum ether (20:1). The organic phase was taken, dried, concentrated and separated by silica gel column chromatography (10% ea in PE) to give 1.16g of product, yield: 100%.
/>
Synthesis of Compound A-I04. A-S03 (3.62 g,20 mmol), A-S04 (5.12 g,20 mmol) and DMAP (0.85 g,7 mmol) were dissolved in DCM (60 mL), cooled to 0deg.C, DCC (4.32 g,21 mmol) was added, and warmed to room temperature and stirred overnight. The reaction solution was filtered, concentrated and purified by column separation (silica gel column, eluent PE: ea=50:1) to give 8.0g of the product, yield: 89%.
Synthesis of Compound A-I05. A-I04 (2.25 g,5.0 mmol), A-S05 (5.26 g,50.0 mmol) and EtOH (3.0 mL) were added to a thick-walled pressure-resistant bottle and heated to 90℃for reaction overnight. The reaction solution was concentrated, extracted with ethyl acetate/water (1:1), and the organic phase was washed once with water and twice with saturated brine. The organic phase was concentrated to give 2.26g of product in 100% yield.
Synthesis of Compound F-01. A-I05 (300 mg,0.676 mmol), A-I03 (469 mg,1.01 mmol), DIEA (222 uL,1.27 mmol), KI (34 mg,0.2 mmol), THF (1.0 mL) and CH were combined 3 CN (1.0 mL) was added to the back-wall pressure flask, and the mixture was heated to 80℃overnight for reaction. The reaction solution was concentrated, dissolved in ethyl acetate, washed once with saturated sodium bicarbonate solution/water (1:2), saturated brine was washed once, the organic phase was dried, concentrated, and purified by column separation (silica gel column, eluent 1.5-3% meoh in DCM) to give 410mg of product in 73% yield.
The compounds F-02 to F-06, F-08 to F-11, F-15 to F-21, F-23, F-25 to F-31 can also be prepared by the method of example 1, and are not described in detail herein. Wherein the synthesis method of A-I10 was synthesized by the synthesis method of A-I10 in example 4.
Example 2:
synthesis of Compound F-07. A-I03 (500.0 mg,1.08 mmol), A-S09 (38.5 mg,0.43 mmol), DIEA (167.7 mg,1.30 mmol), KI (14.4 mg,0.09 mmol), THF (1.0 mL) and CH were combined 3 CN (1.0 mL) was added to the back-wall pressure flask, and the mixture was heated to 80℃overnight for reaction. The reaction solution was concentrated, dissolved in ethyl acetate, washed once with saturated sodium bicarbonate solution/water (1:2), saturated brine was washed once, the organic phase was dried, concentrated, and purified by column separation (silica gel column, eluent 3% meoh in DCM) to give 280mg of product in 76% yield.
Example 3:
synthesis of Compound A-I13. Triphosgene (1.01 g,3.41 mmol) was dissolved in DCM (50 mL), DMAP (4.17 g,33.12 mmol) dissolved in 50mL DCM was added dropwise under ice bath conditions, stirring was continued for 10 min under ice bath conditions after the addition was completed, then A-S06 (1.01 g,3.41 mmol) was added dropwise under ice bath conditions, gradually returned to room temperature, stirring was continued for 2 hours, then A-S08 was added dropwise under ice bath conditions, then gradually returned to room temperature, and stirring was continued for 2 hours. The reaction mixture was washed with a saturated sodium hydrogencarbonate solution (100 mL. Times.2) and a saturated brine (100 mL. Times.1) in this order, dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified by filtration over silica gel and concentrated to give 4g of crude product which was directly subjected to the next reaction.
Synthesis of Compounds A-I14. Reference is made to the synthetic method of A-I03 in example 1.
Synthesis of Compound A-I15. A-I14 (1.0 g,2.74 mmol), A-S07 (1.68 g,27.4 mmol) was dissolved in ethanol (5 mL) and the reaction was performed at 88℃for 12 hours with heating and sealing. Cooled to room temperature, 100mL of ethyl acetate was added, and the mixture was washed successively with a saturated sodium hydrogencarbonate solution (100 mL. Times.2) and a saturated brine (100 mL. Times.1), dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified using column separation (DCM: etoh=50:1) to give 0.59g of product, yield: 62%.
Synthesis of Compound F-22. A-I15 (0.30 g,0.87 mmol), A-I13 (0.61 g,1.31 mmol), DIPEA (0.23 g,1.74 mmol), KI (14 mg,0.09 mmol) were dissolved in THF/MeCN (2.0 mL+2.0 mL) and the reaction was capped at 86℃for 12h. After cooling to room temperature, ethyl acetate (100 mL) was added, and the organic phase was washed successively with a saturated sodium bicarbonate solution (100 mL. Times.2) and a saturated brine (100 mL. Times.1), dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified using column separation (DCM: etoh=50:1) to give 0.28g of product, yield: 44%. Using the procedure of example 3, with the corresponding starting materials exchanged, this preparation method gives: f-12 to F-14.
Example 4:
compound synthesis route:
the specific method for synthesizing the compound comprises the following steps:
synthesis of Compound A-I06. A-S06 (3.85 g,15 mmol), N, N' -disuccinimidyl carbonate (5.84 g,22.8 mmol) and DMAP (2.75 g,22.5 mmol) were added to DMF (60 mL), heated to 75deg.C and stirred overnight. The reaction solution was poured into 300mL of water, and extracted 2 times with ethyl acetate. The organic phases were mixed and washed three times with saturated saline. The organic phase is taken, dried and concentrated, and purified by silica gel column chromatography (silica gel column, eluent is PE: EA=50:1) to obtain 1.8g of product with the yield of 42 percent.
Synthesis of Compound A-I07. A-I06 (1.8 g,4.53 mmol), A-S01 (636 mg,5.43 mmol) and DMAP (554 mg,4.53 mmol) were added to DMF (30 mL), heated to 60℃and stirred overnight. The reaction solution was poured into 300mL of water, and extracted 2 times with ethyl acetate. The organic phases were mixed and washed three times with saturated saline. The organic phase was taken, dried and concentrated to give 1.84g of product in 100% yield, which was used directly in the next reaction.
Synthesis of Compound A-I08. Ms was slowly added to a solution of A-I07 (1.84 g,4.53 mmol), DMAP (61 mg,0.5 mmol) and TEA (2.5 mL,18 mmol) in DCM (60 mL) at 0deg.C 2 A solution of O (1.57 g,9 mmol) in DCM. After stirring at 0deg.C for 30 min, quench with water (100 mL). The organic phase was separated, washed once with water, 10% citric acid once with saturated brine once. The organic phase was dried and concentrated to give 2.05g of crude product, which was used directly in the next reaction.
Synthesis of Compound A-I09. A-I08 (2.05 g,4.29 mmol) and LiBr (1.2 g,13.6 mmol) were added to THF (25 mL), heated to 45℃and stirred overnight. Filtration over silica gel, concentration of the filtrate, and purification by chromatography on a silica gel column (column, eluent: PE: ea=10:1) gave 1.84g of the product in 93% yield.
Synthesis of Compound A-I10. A-I09 (2.00 g,4.3 mmol) was added to a suspension of NaH (208 mg,8.6 mmol) and MeI (538 uL,8.6 mmol) in THF (120 mL) at 0deg.C. The mixture was warmed to room temperature and stirred for 48 hours. Concentrated, sodium bicarbonate solution was added and extracted three times with ethyl acetate/petroleum ether (20:1). The organic phase is taken, dried, concentrated and separated by silica gel column chromatography (12% EAin PE) to obtain 2.01g of product with the yield: 98%.
Synthesis of Compound A-I11. A-S07 (300.0 mg,4.91 mmol) was dissolved in DMF (3.4 mL), A-I10 (757.3 mg,1.64 mmol), DIEA (634.8 mg,4.91 mmol) was added, and the mixture was reacted at 50℃for 18h. After cooling to room temperature, ethyl acetate (40 mL) was added, and the organic phase was washed with half-saturated brine (5 mL. Times.3) and saturated brine in this order, dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified by column chromatography (DCM: etoh=20:1) to give 402.1mg of product. Yield: 55%.
Synthesis of Compound A-I11. Reference example 1 shows a method for synthesizing the compound A-I01.
Synthesis of Compound F-24. A-I12 (300.0 mg, 858.7. Mu. Mol) was dissolved in DMF (1.0 mL), DIEA (222.0 mg,1.72 mmol) was added, and A-I11 (588.4 mg,1.29 mmol) was reacted at 70℃for 12h. After cooling to room temperature, ethyl acetate (40 mL) was added, and the organic phase was washed with half-saturated brine (5 mL. Times.3) and saturated brine in this order, dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified by column chromatography (DCM: etoh=20:1) to give 362.1mg of product. Yield: 42%.
The hydrogen spectrum data of the compounds are shown below and in fig. 1:
/>
as an application, the above compounds can be used for preparing a composition for medical use, the composition comprising: a carrier, a carried medicament and a medicinal auxiliary agent.
The carrier comprises: one or more lipid compounds containing urethane linkages, a helper lipid, a structural lipid, a polymer conjugated lipid or an amphiphilic block copolymer.
As an example, the carrier is Lipid Nanoparticle (LNP), the average size of the lipid nanoparticle is 30-200nm, and the polydispersity index of the nanoparticle preparation is less than or equal to 0.3. It should be noted that: any nanoparticle prepared by adopting the lipid compound with the structure is in the scope of the patent, and is taught by the invention; such as: in addition to the lipid nanoparticle, it is also possible to form one or more doped nanoparticles of lipid compounds containing urethane bonds with a polymer, such as: PLGA-PEG, PLA-PEG, PCL, PBAE (Poly beta-amino acid) and the like are not exhaustive herein.
The lipid-aiding agent comprises: phosphatidylcholine, phosphatidylethanolamine, sphingomyelin (SM), sterols and derivatives thereof, ceramide, charged lipids, or a combination of several of them; phosphatidylcholine as one preferred includes: DSPC, DPPC, DMPC, DOPC, POPC; phosphatidylethanolamine as a preferred type is DOPE; sterols as a preferred cholesterol; charged lipids are as an example DOTAP, DOTMA, 18PA; it is not intended to be exhaustive and it is within the scope of the invention to suggest any composition of lipid compounds employing the structures of the present invention. The choice of the auxiliary lipid is not limited and is not limited, and any lipid compound adopting the structure of the invention is within the scope of the invention and is taught by the invention.
Structural lipids include: cholesterol, non-sterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, lycorine, ursolic acid, alpha-tocopherol or corticosteroid. The choice of structural lipids is not limited and is not intended to be exhaustive, as long as lipid compounds employing the structures of the present invention are within the scope of the present invention.
The polymer conjugated lipid is a pegylated lipid; as one example, the pegylated lipid comprises: one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, or PEG-modified dialkylglycerol. It is not intended to be exhaustive, and the choice of polymer conjugated lipids is not limited, as long as lipid compounds employing the structures of the present invention are within the scope of the present invention, and are all taught by the present invention.
As an example, the amphiphilic block copolymer may include: a combination of one or more of polylactic acid-polyglycolic acid copolymer (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyorthoester, polyanhydride, poly (β -amino ester) (PBAE), or polyethylene glycol (PEG) modified amphiphilic block copolymer. It should be noted that: the examples herein are not exhaustive as long as the use of the structural lipids of the present invention is within the scope of the present invention.
The carried drugs include: one or more of a nucleic acid molecule, a small molecule compound, a polypeptide or a protein. It is not exhaustive, and any type of drug can be used in the present invention, as long as the lipid compound having the structure of the present invention is adopted, and the lipid compound is within the scope of the present invention.
The pharmaceutical auxiliary comprises: one or more of a diluent, a stabilizer, a preservative or a lyoprotectant. It is not exhaustive, and any lipid compound adopting the structure of the present invention, regardless of the pharmaceutical adjuvant selected for compounding, is within the scope of the present invention.
Experiment one: preparation of mRNA-LNP
mRNA-LNP was prepared by the following experimental method.
Lipid compounds (Lipid) and synthetic comparative Lipid compounds in Table 1, DOPE (Aivelo (Shanghai) medical science Co., ltd.), cholesterol (Aivelo (Shanghai) medical science Co., ltd.), and PEG-Lipid were dissolved in ethanol at a designed prescription ratio (Lipid/DOPE/Cholesterol/Lipid-PEG of 40/20/38.5/1.5 (molar ratio)) to prepare a Lipid ethanol solution (concentration of Lipid: 20 mg/mL). The Lipid compound (the dioic vaccine BNT162b 2) corresponding to the commercial comparative sample ALC0315 in Table 1 was dissolved in ethanol at an optimum ratio of Lipid/DSPC/Cholesterol/Lipid-PEG of 46.3/9.4/42.7/1.6 (molar ratio), to prepare a Lipid ethanol solution (concentration of Lipid 20 mg/mL).
Step two: mRNA was prepared at a Lipid Nanoparticle (LNP) to mRNA mass ratio of 10:1 to 30:1, diluted to 0.2mg/mL using citrate or sodium acetate buffer (ph=3 or 5).
And thirdly, fully and uniformly mixing the lipid ethanol solution obtained in the step one with the mRNA solution according to the volume ratio of 1:5 to 1:1. The obtained nanoparticles were purified by ultrafiltration and dialysis, and after filtration and sterilization, the particle size of mRNA-LNP (lipid nanoparticle encapsulating mRNA) and PDI were characterized by using Malvern Zetasizer Nano ZS, and the encapsulation efficiency of mRNA was determined by using a Ribogreen RNA quantitative determination kit (Thermo Fisher). As shown in Table 1 and FIG. 2, the lipid nanoparticles of the present invention can form stable nanostructures, have a narrow size distribution, and have a size varying with the structures of different lipid nanoparticles, ranging from 60 to 120 nm.
TABLE 1
/>
/>
/>
/>
Experiment II: transfection efficiency validation experiment:
male ICR mice (6-8 week, shanghai Jieshi laboratory animals Co., ltd.) were kept at 22.+ -. 2 ℃ and a relative humidity of 45-75% for a 12h light/dark cycle. mRNA (luciferase mRNA) encoding luciferase was used as a reporter gene. Luciferase catalyzes luciferin to generate bioluminescence, and the transfection efficiency of LNP is reflected by detecting the intensity of bioluminescence in unit time. Taking luciferase mRNA (from ApexBio Technology) as an example, mRNA-LNP samples F-01 to F-31 obtained in experiment one, a commercial comparative sample ALC0315, comparative sample F-00; the above samples were administered by intramuscular injection at a dose of 100 μg/kg mRNA, respectively, for two mice, two legs per group of samples. At a specific time point, fluorescein (20 mug/mL) was injected into the abdominal cavity of the mice, and after 5 minutes, the mice were placed on a living body imager of the small animals to measure fluorescence intensity, and the final result is represented by average fluorescence intensity, and the experimental results of the fluorescence intensity after the intraperitoneal injection administration of the mice are shown in Table 2.
TABLE 2
/>
/>
/>
/>
Analysis of results:
ALC0315 is a commercial control sample (pyro BNT162b 2). The LNP samples of the invention containing F-01 to F-31 were compared with the experimental results of ALC0315 and F-00 as follows: the transfection efficiency of the lipid nanoparticle sample prepared by the lipid compound with the structure is obviously higher than that of a commercial comparison sample, and the lipid nanoparticle sample has obvious progress and unexpected effect.
Experiment III: biocompatibility experiments
Cell viability was determined using the CCK-8 (cell counting kit-8) kit. Hep3B cells (100. Mu.L, cell density 2X 10) 4 Each mL) was added to a 96-well plate, incubated in a cell culture incubator for 24 hours, then the cell culture broth was removed from each well, and 100. Mu.L of fresh cell culture broth containing LNP with mRNA 20. Mu.g/mL was added, and incubated with cells for 4 hours. Subsequently, the cell supernatant was removed, fresh cell culture medium was added, and incubation was continued for 20h. Then, the supernatant was removed, 100. Mu.L of fresh cell culture solution containing CCK-8 working solution (10. Mu.L/mL) was added, incubated for 2 hours, and blank wells were set: adding a cell culture solution containing CCK-8 working solution. Absorbance at 450nm of each well (bubbles cannot appear in the well plate during detection) was detected using a multifunctional microplate detector, and cells not treated with LNP were used as a control group, and their cell viability was set to 100%.
Cell viability (%) = [ A1-A0]/[ A2-A0] ×100;
a1 is absorbance of the dosing group, A0 is absorbance of the blank group, and A2 is absorbance of the control group. The experimental results are shown in table 3.
TABLE 3 Table 3
/>
The experimental results showed that the cell viability was greater than 90% at the defined LNP concentration, with no apparent cytotoxicity.
Experiment IV: lipid nanoparticle Low temperature storage stability experiment
Taking sample F-01 as an example, lipid nanoparticles prepared according to the formulation were stored at low temperature at 4 ℃, and at different time points (0 day, 6 day, 10 day, 15 day, 30 day, 45 day), the particle Size (Size) of mRNA-LNP (mRNA-entrapped lipid nanoparticles) was characterized by Malvern Zetasizer Nano ZS to approximate PDI, and the encapsulation efficiency of mRNA was determined by using the Ribogreen RNA quantitative assay kit (Thermo Fisher). The measurement results are shown in Table 4.
TABLE 4 Table 4
As can be seen from table 4: the LNP (lipid nanoparticle) formed by the lipid molecules can be stored for 90 days at low temperature, the particle size and the encapsulation efficiency are stable, the transportation and the storage of products are convenient, and the LNP (lipid nanoparticle) is suitable for industrial production.
Experiment five: animal test for immune Effect
Material preparation: female Balb/c mice with six weeks of age, 15-20 g of body weight, 20 mice are fed into an experimental environment with the temperature of 22+/-2 ℃ and the relative humidity of 45-75%, and the light/dark period is 12 hours. After the mice are purchased and adapted in animal houses for one week, formal animal tests can be carried out. The 20 mice were randomly divided into 4 groups, the first group was injected with equal volume of PBS (negative control group) in the hind leg muscle, the second group was injected with a mixture of commercial comparative sample ALC-0315 (positive control group), 5. Mu.g of mRNA, PBS, the third group was injected with comparative sample F-00 (control group), 5. Mu.g of mRNA, PBS, the fourth group was injected with sample F-01 (test group), 10. Mu.g of mRNA, PBS; the mRNA is mRNA which is synthesized based on an autonomously designed template through in vitro transcription and can express Spike full length.
The experimental process is as follows: on days 0 and 14, the mRNA-entrapped LNP mixtures were injected intramuscularly into Balb/c mice in the four groups above. Ocular blood collection was performed on days 13 and 21, and after incubation at 37℃for 1 hour, the blood samples were centrifuged at 3500rpm for 15 minutes, and the supernatants were analyzed. The titer of antibodies specific for Delta variant S1 protein from both primary and secondary mouse sera was detected by self-made ELISA kit.
The specific procedure for detecting the titre of Delta variant S1 protein-specific antibodies from both primary and secondary mouse sera was as follows: spike S1 recombinant protein was added to 96-well plates at 0.25. Mu.g per well and left overnight at 4 ℃. The next day, the fluid in the wells was discarded and blocked with 5% BSA in PBST (200 ul) for 1h at 37 ℃. Afterwards, the liquid in the holes is discarded, 200ul of PBST washing liquid is used for washing for 3 times, each time is 3min, and the plate is thrown away for airing. Mouse serum was diluted with PBS (dilution ratio listed as 1:20000) or standards were diluted with PBS to a range of concentrations (stock 1ug/ul, half-diluted, total of 14 standard curves). 100. Mu.L of diluted sample and standard were added to the air and incubated at 37℃for 2h. The liquid in the holes is discarded, 200ul of PBST washing liquid is used for washing for 3 times, each time is 3min, and the plate is thrown off for airing. Goat anti-mouse IgG HRP (PBS 1:5000 dilution) was added at 100ul per well, 37℃for 1h. The liquid in the holes is discarded, 200ul of PBST washing liquid is used for washing for 3 times, each time is 3min, and the plate is thrown off for airing. TMB substrate solution A and solution B were mixed in equal proportions, 100. Mu.L per well, and left at 37℃for several minutes (3-5 mins) protected from light. When absorbance is measured at 650nm and the highest absorbance value is around 1.5, 100ul of stop solution can be added. The absorbance at 450nm was measured within 15min after addition of the stop solution. The IgG content of each group was calculated according to the standard curve formula.
The experimental results show that: the positive control group, the control group and the test group can generate antibodies specific to the S1 protein, the antibody titer of the test group is obviously higher than that of the positive control group, and the test group can efficiently deliver mRNA into cells to express antigen so as to excite immune reaction in vivo to generate corresponding antibodies and play a protection function.
In summary, the novel lipid compound structure of the present invention has outstanding substantive characteristics, and the above experiments prove that the novel lipid compound of the present invention uses a tertiary amine-containing group as a head, two hydrophobic groups as tails, and one side of the two hydrophobic groups is respectively introduced with- (C=O) O-, -O (C=O) -, -NH (C=O) O-, -O (C=O) NH-, -O (C=O) O-, - (C=O) S-, -S (C=O) -, alkylated urethane bonds, one side is introduced with an alkylation urethane bond, and at least one of the two hydrophobic tail parts is introduced with the alkylation urethane bond, so that LNP composed of the compound with the structure can cause LNP to break cell endosome membrane more easily, and enhance the escape capacity of LNP endosome; and has better transfection effect compared with LNP (gabion sample) already used in the market; the lipid compound disclosed by the invention is novel in structure, has unexpected technical effects, is unobvious and is creative.
What needs to be explained here is: the lipid compound is a raw material of medicines and a medicine product, does not relate to any treatment method or diagnosis method of diseases, and belongs to the scope of patent rights granted. The application range of the present invention is not limited, and the present invention can be applied to the field of vaccines, protein substitution therapy, gene editing, cell therapy, etc., and the examples are not exhaustive, and any lipid compound employing the structural features of the present invention is within the scope of the present invention.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be appreciated by persons skilled in the art that the above embodiments are not intended to limit the invention in any way, and that all technical solutions obtained by means of equivalent substitutions or equivalent transformations fall within the scope of the invention.

Claims (12)

1. A lipid compound, wherein said lipid compound is selected from the group consisting of: 。
2. the lipid compound of claim 1, wherein the lipid compound is selected from the group consisting of: 。
3. a composition comprising the lipid compound according to any one of claims 1-2, a stereoisomer thereof, a tautomer thereof or a pharmaceutically acceptable salt thereof.
4. A composition according to claim 3, wherein the composition comprises: a carrier, a medicament for carrying, a pharmaceutical adjuvant, and said carrier comprising a lipid compound according to any one of claims 1-2.
5. The composition of claim 4, wherein the carrier further comprises: a co-lipid, a structural lipid, a polymer conjugated lipid, or an amphiphilic block copolymer, or a combination thereof.
6. The composition of claim 5, wherein the molar ratio of lipid compound to co-lipid is from 0.5:1 to 15:1.
7. The composition of claim 5, wherein the molar ratio of lipid compound to structured lipid is from 0.5:1 to 5:1.
8. The composition of claim 5, wherein the molar ratio of lipid compound to polymer conjugated lipid is from 5:1 to 250:1.
9. The composition of claim 5, wherein the molar ratio of the lipid compound to the amphiphilic block copolymer is from 1:1 to 200:1.
10. The composition of claim 4, wherein the carrier is a lipid nanoparticle having an average size of 30-200nm and a polydispersity index of 0.3 or less.
11. The composition of claim 4, wherein the drug loaded comprises: a nucleic acid molecule, a small molecule compound, a polypeptide or a protein, or a combination thereof.
12. The composition of claim 4, wherein the pharmaceutically acceptable adjuvant comprises: a diluent, stabilizer, preservative, or lyoprotectant, or a combination thereof.
CN202310007835.9A 2023-01-04 2023-01-04 Lipid compound containing alkylated carbamate bond and application thereof Active CN116063205B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310007835.9A CN116063205B (en) 2023-01-04 2023-01-04 Lipid compound containing alkylated carbamate bond and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310007835.9A CN116063205B (en) 2023-01-04 2023-01-04 Lipid compound containing alkylated carbamate bond and application thereof

Publications (2)

Publication Number Publication Date
CN116063205A CN116063205A (en) 2023-05-05
CN116063205B true CN116063205B (en) 2024-02-02

Family

ID=86169304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310007835.9A Active CN116063205B (en) 2023-01-04 2023-01-04 Lipid compound containing alkylated carbamate bond and application thereof

Country Status (1)

Country Link
CN (1) CN116063205B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947669B (en) * 2022-09-30 2024-04-12 荣灿生物医药技术(上海)有限公司 Ionizable lipid compound with high transfection efficiency and application thereof
CN116891423B (en) * 2023-07-07 2024-03-01 荣灿生物医药技术(上海)有限公司 Lipid compound, composition, preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036030A1 (en) * 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN113402405A (en) * 2021-04-08 2021-09-17 厦门赛诺邦格生物科技股份有限公司 Cationic lipid, liposome containing cationic lipid, nucleic acid pharmaceutical composition containing liposome, preparation and application thereof
CN113999128A (en) * 2021-11-25 2022-02-01 苏州科锐迈德生物医药科技有限公司 Lipid compound, lipid carrier based on lipid compound, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CN114206827A (en) * 2020-04-09 2022-03-18 苏州艾博生物科技有限公司 Lipid nanoparticle compositions
CN114890907A (en) * 2022-03-31 2022-08-12 荣灿生物医药技术(上海)有限公司 Cationic lipid compound and preparation method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036030A1 (en) * 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN114206827A (en) * 2020-04-09 2022-03-18 苏州艾博生物科技有限公司 Lipid nanoparticle compositions
CN113402405A (en) * 2021-04-08 2021-09-17 厦门赛诺邦格生物科技股份有限公司 Cationic lipid, liposome containing cationic lipid, nucleic acid pharmaceutical composition containing liposome, preparation and application thereof
CN113999128A (en) * 2021-11-25 2022-02-01 苏州科锐迈德生物医药科技有限公司 Lipid compound, lipid carrier based on lipid compound, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
CN114890907A (en) * 2022-03-31 2022-08-12 荣灿生物医药技术(上海)有限公司 Cationic lipid compound and preparation method and application thereof

Also Published As

Publication number Publication date
CN116063205A (en) 2023-05-05

Similar Documents

Publication Publication Date Title
CN116063205B (en) Lipid compound containing alkylated carbamate bond and application thereof
US20230286902A1 (en) Lipid nanoparticle composition
WO2022166213A1 (en) Ionizable lipid molecule, preparation method therefor, and application thereof in preparation of lipid nanoparticle
CN114901253A (en) Improved lipid nanoparticles for delivery of nucleic acids
CN115784920B (en) Ionizable lipid compound with high transfection efficiency and application thereof
CN114890907B (en) Cationic lipid compound and preparation method and application thereof
AU2022434120A1 (en) Cationic lipid compound, composition containing same and use thereof
TW202214566A (en) Lipid compounds and lipid nanoparticle compositions
CA2969664A1 (en) Cationic lipid
WO2023186149A1 (en) Lipid compound, composition containing same, and use thereof
CN117177954B (en) Ionizable lipids and compositions thereof for nucleic acid delivery
CN114206463B (en) Lipid compounds and lipid nanoparticle compositions
WO2024109665A1 (en) Carbamate-bond-containing lipid compounds and use thereof
US20230348362A1 (en) Lipid compounds and lipid nanoparticle compositions
WO2024022263A1 (en) Lipid compound and lipid nanoparticle composition
WO2023116804A1 (en) Lipid compound and lipid nanoparticle composition
CN116947669B (en) Ionizable lipid compound with high transfection efficiency and application thereof
JP5914418B2 (en) Lipid particle, nucleic acid delivery carrier, composition for producing nucleic acid delivery carrier, lipid particle production method and gene introduction method
TW202330457A (en) Lipid compounds and lipid nanoparticle compositions
TW202329986A (en) Lipid compounds and lipid nanoparticle compositions
WO2024067639A1 (en) Ionizable lipid compound having high transfection efficiency and use thereof
CN114848831A (en) Coated nano preparation and preparation method and application of carrier thereof
CN117659091A (en) Phospholipid cationic lipid compound, lipid nanoparticle prepared from phospholipid cationic lipid compound and application of lipid nanoparticle
CN116891423B (en) Lipid compound, composition, preparation method and application thereof
WO2024083172A1 (en) Lipid compound and lipid nanoparticle composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240531

Address after: Room 418, Building 56, No. 248 Guanghua Road, Minhang District, Shanghai, 2011

Patentee after: Weishikang Animal Health (Shanghai) Co.,Ltd.

Country or region after: China

Address before: No. 161 Changjiang Street, Changjiang Farm, Chongming District, Shanghai, 202178

Patentee before: Shanghai Zhenyao Biotechnology Partnership (limited partnership)

Country or region before: China